BDX Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 12.41%. Becton Dickinson &'s return on equity of 6.75% beat Boston Scientific's return on equity of 8.96%.

Becton Dickinson & has a consensus price target of $275.03, signalling upside risk potential of 31.38%. On the other hand Boston Scientific has an analysts' consensus of $115.37 which suggests that it could grow by 19.22%. Given that Becton Dickinson & has higher upside potential than Boston Scientific, analysts believe Becton Dickinson & is more attractive than Boston Scientific.

Becton Dickinson & has a beta of 0.349, which suggesting that the stock is 65.131% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.9%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than Boston Scientific quarterly revenues of $4.6B. Becton Dickinson &'s net income of $303M is lower than Boston Scientific's net income of $566M. Notably, Becton Dickinson &'s price-to-earnings ratio is 34.78x while Boston Scientific's PE ratio is 77.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.95x versus 8.59x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 5.86% compared to Becton Dickinson &'s net margin of -58.2%. Becton Dickinson &'s return on equity of 6.75% beat Masimo's return on equity of -23.05%.

Becton Dickinson & has a consensus price target of $275.03, signalling upside risk potential of 31.38%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 18.91%. Given that Becton Dickinson & has higher upside potential than Masimo, analysts believe Becton Dickinson & is more attractive than Masimo.

Becton Dickinson & has a beta of 0.349, which suggesting that the stock is 65.131% less volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.9%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend. Becton Dickinson &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than Masimo quarterly revenues of $600.7M. Becton Dickinson &'s net income of $303M is higher than Masimo's net income of -$349.6M. Notably, Becton Dickinson &'s price-to-earnings ratio is 34.78x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.95x versus 4.25x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 26.88%. Becton Dickinson &'s return on equity of 6.75% beat ResMed's return on equity of 25.56%.

Becton Dickinson & has a consensus price target of $275.03, signalling upside risk potential of 31.38%. On the other hand ResMed has an analysts' consensus of $269.42 which suggests that it could grow by 24.48%. Given that Becton Dickinson & has higher upside potential than ResMed, analysts believe Becton Dickinson & is more attractive than ResMed.

Becton Dickinson & has a beta of 0.349, which suggesting that the stock is 65.131% less volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.9%. ResMed offers a yield of 0.96% to investors and pays a quarterly dividend of $0.53 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are larger than ResMed quarterly revenues of $1.3B. Becton Dickinson &'s net income of $303M is lower than ResMed's net income of $344.6M. Notably, Becton Dickinson &'s price-to-earnings ratio is 34.78x while ResMed's PE ratio is 25.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.95x versus 6.48x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 5.86% compared to Becton Dickinson &'s net margin of 8.48%. Becton Dickinson &'s return on equity of 6.75% beat Stryker's return on equity of 15.22%.

Becton Dickinson & has a consensus price target of $275.03, signalling upside risk potential of 31.38%. On the other hand Stryker has an analysts' consensus of $423.15 which suggests that it could grow by 16.58%. Given that Becton Dickinson & has higher upside potential than Stryker, analysts believe Becton Dickinson & is more attractive than Stryker.

Becton Dickinson & has a beta of 0.349, which suggesting that the stock is 65.131% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Becton Dickinson & has a quarterly dividend of $1.04 per share corresponding to a yield of 1.9%. Stryker offers a yield of 0.9% to investors and pays a quarterly dividend of $0.84 per share. Becton Dickinson & pays 64.52% of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Becton Dickinson & quarterly revenues are $5.2B, which are smaller than Stryker quarterly revenues of $6.4B. Becton Dickinson &'s net income of $303M is lower than Stryker's net income of $546M. Notably, Becton Dickinson &'s price-to-earnings ratio is 34.78x while Stryker's PE ratio is 46.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Becton Dickinson & is 2.95x versus 6.19x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.